Budoucí P/E společnosti Edesa Biotech

Jaká je hodnota metriky Budoucí P/E společnosti Edesa Biotech?

Hodnota metriky Budoucí P/E společnosti Edesa Biotech, Inc. je 0.17

Jaká je definice metriky Budoucí P/E?



Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Budoucí P/E společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Edesa Biotech

Čemu se věnuje společnost Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou budoucí p/e podobnou společnosti Edesa Biotech